Cannabis Policy

October 27, 2026

Kansas voters are backing marijuana legalization across party lines by substantial margins, according to the 2026 Kansas Speaks Survey released Monday. A Fort Hays State University poll of 603 adults found 58 percent support recreational legalization and 65 percent back medical cannabis access—including majorities of Democrats, Republicans, and independents on both measures. Support climbs to 61 percent when legalization is framed as a revenue-raising mechanism, suggesting voters see potential financial benefits. Context The findings arrive as Democratic gubernatorial candidate Cindy Holscher is making legalization a campaign centerpiece, arguing Kansas loses tax revenue while neighboring states profit from legal dispensaries just across the border.

Federal civil rights advocacy is amplifying the push for legalization at the national level. The Leadership Conference on Civil and Human Rights, representing over 240 organizations, disclosed Monday that it has lobbied the U.S. Senate in support of S. 5022, the Cannabis Administration and Opportunity Act. The bill, introduced in July by Senators Cory Booker, Chuck Schumer, and Ron Wyden, would remove marijuana entirely from the Controlled Substances Act, establish federal regulation and taxation, and fund expungement of past convictions in communities harmed by prohibition. The legislation remains in the Senate Finance Committee with no scheduled vote.

California's highest court is reshaping cannabis conviction law. An appellate court ruled last week that some felony cannabis cultivation convictions may be reduced to misdemeanors, reversing a lower court decision in People v. Baxter. The ruling determines that certain aggravated cultivation offenses—even those involving environmental harm allegations—qualify as "wobblers" that trial courts can reclassify, reflecting how legalization has changed the state's approach to historical enforcement actions.

Money Multiple states are grappling with regulatory and tax friction that threatens industry stability. Texas faces escalating litigation over its smokable hemp ban and fee increases: the Texas Hemp Constitutional Alliance and Green Nation filed suit this week claiming state health officials exceeded their authority, adding to multiple pending cases challenging the regulations. One lawsuit from four hemp retailers estimates the ban has caused 36,000 job losses and billions in industry losses. In Ohio, Vext Science sued Pierce Township, alleging that a 4.5 percent gross revenue fee on cannabis retailers constitutes illegal extortion. Michigan's Republican lieutenant gubernatorial candidate Jay DeBoyer announced plans to suspend the state's 24 percent cannabis tax for 12 months to provide business relief.

Rhode Island's hemp sector faces a December 11 federal deadline that leaves operators in limbo. The state's Cannabis Control Commission issued guidance allowing hemp businesses to quarantine inventory exceeding the new federal 0.4 milligram THC potency limit—but not sell it—if Congress doesn't reverse course before the deadline. The policy avoids forced destruction amid regulatory uncertainty, though operators like Lovewell Farms say the outcome remains contradictory: they can legally grow but cannot legally distribute their harvest.

Notable California courts are creating pathways for conviction relief while federal advocates push comprehensive reform. The combination of state judicial recalibration and organized civil rights pressure reflects how cannabis policy is shifting from pure prohibition toward systems that account for legalization's legal reality—and the documented harm caused by decades of enforcement against a substance now widely recognized as having medical value and generating significant tax revenue.

October 26, 2026

Michigan Republicans are making moves to freeze the state's 24% wholesale marijuana tax for a year. State Representative Jay DeBoyer announced plans to introduce legislation suspending the levy, arguing it has failed to generate the $420 million annually that lawmakers projected when Governor Gretchen Whitmer signed the tax into law in October 2025. Money Collections during the first several months fell substantially short of expectations, and DeBoyer contends the additional financial burden is making it harder for licensed cannabis businesses to compete with unregulated sellers. The proposal differs from other Republican efforts—House Bill 6224 would repeal the tax entirely, and gubernatorial nominee John James has pledged to eliminate or significantly reduce it if elected—but DeBoyer's temporary suspension aims to give legislators time to reassess whether the tax structure itself needs reform.

Context The Michigan case illustrates a broader pattern: cannabis tax projections often rest on assumptions about market behavior that don't hold up once implementation begins. When states layer multiple taxes—Michigan now collects the 24% wholesale levy plus a 10% retail excise tax plus standard 6% sales tax—total effective tax rates climb steeply, and price-sensitive consumers shift toward illegal suppliers. Licensed operators face razor-thin margins, and revenue projections built on legal-market volume become unrealistic almost immediately.

Across the country, voters in Massachusetts are rejecting an attempt to roll back legalization entirely. Ballot Question 8 would repeal the state's adult-use cannabis framework, but polling and reporting from the Cape Cod Times indicates voters do not want to reverse course. Context This reflects a national trend: once voters legalize cannabis, they rarely vote to criminalize it again. The question becomes not whether legalization stays but how to fix implementation—tax rates, licensing, supply chain efficiency—rather than whether to abandon the market altogether.

Meanwhile, a constitutional question is reaching the high court: can the federal government ban gun ownership for cannabis users? The Second Amendment intersection with federal cannabis scheduling remains unresolved, and the case highlights a persistent contradiction in American law. States have legalized cannabis for medical and adult use, but federal law still classifies it as Schedule I, creating legal limbo for lawful state consumers who also own firearms.

On the health front, a study in USA Today linked marijuana legalization to a rise in heart-related hospitalizations, adding to the ongoing public health conversation. The research joins earlier findings that have documented both risks and benefits—seizure reduction, cancer cell suppression, Alzheimer's plaque reduction—and underscores that cannabis, like any substance, carries context-dependent effects. The difference remains stark when compared to alcohol, which causes roughly 95,000 U.S. deaths annually, or prescription opioids, which kill over 16,000 per year. Cannabis has recorded zero overdose deaths in human history. The question for regulators becomes not zero-risk—which doesn't exist for any substance—but proportional response and honest risk assessment.

October 25, 2026

A cascade of legal challenges is upending Texas's patchwork cannabis regulations, as hemp companies, smokable THC retailers, and cannabis industry players mount coordinated lawsuits against the state's increasingly restrictive rules. Another lawsuit was filed this week seeking to overturn Texas's ban on smokable THC and its sharp increase in licensing fees for manufacturers and retailers—joining existing legal challenges from hemp shops already contested against the state over new THC regulations. The legal strategy reflects growing frustration in Texas's cannabis market, where companies face a tightening regulatory environment even as momentum shifts nationally toward normalization. What's unfolding in Texas isn't a unified industry opposing government overreach—it's a fragmented market in open conflict, with different cannabis players fighting over who gets to operate, what products remain legal, and whether the state's restrictions will survive judicial review.

The political landscape is shifting faster than the courtrooms can move. Colin Talarico, a candidate for Texas Senate, has signaled he'll partner with the incoming Trump administration to push federal marijuana legalization if elected, while also committing to work toward federal legalization through Congress if he wins. This represents a notable break from Texas's traditional opposition to cannabis reform—and a calculation that legalization is now a winning political position rather than a liability. The broader national ballot this cycle includes marijuana measures in multiple states, signaling that the debate around cannabis has fundamentally changed from whether to legalize to *how* to regulate it properly.

Houston voters are directly confronting this shift this fall, with ballot measures that would effectively deprioritize cannabis law enforcement and establish misdemeanor marijuana possession as Houston Police Department's lowest priority for enforcement. The same ballot includes a proposal to ban no-knock warrants, a tactic historically used in drug enforcement that has resulted in mistaken raids and loss of life. These measures suggest that even at the local level, Texas communities are moving faster than state lawmakers—pushing enforcement priorities toward harm reduction while the state-level legal system remains gridlocked.

Money The financial stakes are real and growing. Texas's hemp and cannabis sector has scaled beyond underground operation into legitimate retail infrastructure, with licensed shops and manufacturers now facing regulatory rules that some describe as prohibitively expensive. The state's higher licensing fees, combined with restrictions on smokable THC products, are reshaping the market's economics—and generating the legal firepower for the current lawsuit wave. Meanwhile, the fragmentation of Texas's cannabis market means multiple economic winners and losers depending on which regulations survive judicial challenge.

The regulatory chaos reveals a deeper problem: Texas has banned several THC products while simultaneously allowing others, creating a legal framework so unclear that even industry participants struggle to understand what's permitted. This uncertainty accelerates the litigation cycle—companies can't plan long-term investments when the legal landscape shifts monthly, and neither state nor business has clarity on the rules that will actually stand. Context Texas is spending resources banning a product that zero Americans have ever fatally overdosed on, while alcohol remains completely legal despite killing roughly 95,000 Americans annually. The disconnect between regulatory energy and public health outcomes suggests the state's cannabis policy is driven by inertia rather than evidence.

October 24, 2026

Federal cannabis rescheduling remains in legal limbo as the Trump administration faces ongoing litigation over the April 2026 decision to move state-regulated medical cannabis from Schedule I to Schedule III. The Department of Justice initiated the reclassification process in 2024 following a December 2025 executive order, but a federal judge stayed the rescheduling case in early October 2026, pushing resolution into at least 2027. The delay creates persistent uncertainty for a market that's already fragmented: 41 states and D.C. now operate medical cannabis programs, and 24 states plus D.C. permit adult recreational use, all while federal law technically maintains prohibition—a contradiction that has defined U.S. cannabis policy for over 50 years.

The financial reality of this limbo is stark. Money State-licensed medical operators operate under an effective tax rate exceeding 70 percent of gross profit because the Internal Revenue Service applies IRC §280E (which bars business expense deductions for Schedule I substances) regardless of state compliance and local regulatory frameworks. Moving cannabis to Schedule III would eliminate that penalty, but wouldn't resolve the banking access problem—federally chartered banks still face prosecution risk under 21 U.S.C. §841 if they service cannabis businesses, even in states where the drug is legal. The SAFER Banking Act, which would protect institutions serving state-legal operators, passed the House in 2023 but stalled in the Senate and hasn't been reintroduced.

Texas illustrates the political contradiction at the heart of the rescheduling debate. Texas hemp legalization in 2019 created a practical problem for law enforcement: distinguishing newly legal hemp from its still-prohibited cannabis cousin became so difficult that marijuana arrests dropped by more than half in the six months following the hemp law's implementation. Yet the state government remains cautious on full legalization. Texas House Speaker Dennis Bonnen, acknowledging that legalization "could be a help" to the state's budget shortfall, nonetheless said he would vote against it, arguing that offsetting costs would limit the actual revenue benefit. Meanwhile, the Texas Republican Party's 2018 platform explicitly endorsed marijuana decriminalization and federal rescheduling—positions that reflect the gap between party apparatus and legislative leadership on the issue.

Context A statewide 70 percent support for legalization emerged in Texas's March 2026 Democratic primary, yet the same political environment produces hesitation from Republican leadership citing budget concerns. The disconnect reveals a pattern: public and party platforms have shifted toward normalization, but elected officials cite operational costs and broader fiscal pressures as reasons for inaction. That dynamic extends nationally—the fact that over 155 million Americans now live in states where cannabis is legal, with zero recorded overdose deaths in human history, contrasts sharply with an enforcement and policy framework built around Schedule I placement.

The litigation ahead will determine whether the April 2026 reclassification survives judicial challenge, but even Schedule III status leaves fundamental problems unresolved. Medical dispensaries will still face the 280E tax burden without congressional action on the SAFER Banking Act. Multi-state operators will navigate a patchwork of 41 different medical frameworks plus 24 recreational regimes, each with distinct licensing, testing, and tax structures. Industry observers report that ongoing uncertainty is already complicating supply chain logistics and business scaling decisions. The outcome of the federal lawsuit could clarify the timeline for tax reform and banking access—but only if rescheduling itself is finally allowed to proceed.